| Trial ID: | L0545 |
| Source ID: | JPRN-UMIN000027362
|
| Associated Drug: |
SGLT2 inhibitor
|
| Title: |
Examination of the liver fibrosis improvement effect with the SGLT2 inhibitor for diabetes complicated by non-alcoholic steatohepatitis. - SGLT2 inhibitor for diabetes complicated by NASH.
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Type 2 diabetes complicated by non-alcoholic fatty liver disease
|
| Interventions: |
SGLT2 inhibitor is administered orally for 1 year or more.
|
| Outcome Measures: |
Histologial changes of liver biopsy of treament are evaluated at two points of the baseline and 1 year after the start of treatment.Fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, and liver fibrosis are evaluated at two points of the baseline and 1 year after the start of treatment.
|
| Sponsor/Collaborators: |
Fukuoka University Hospital
|
| Gender: |
All
|
| Age: |
20years-old80years-old
|
| Phases: |
Not selected
|
| Enrollment: |
30
|
| Study Type: |
Interventional
|
| Study Designs: |
Single arm Non-randomized
|
| Start Date: |
16/05/2017
|
| Completion Date: |
31/03/2019
|
| Results First Posted: |
--
|
| Last Update Posted: |
2 April 2019
|
| Locations: |
Japan
|
| URL: |
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031027
|
